In re ChemoCentryx, Inc. Securities Litigation Settlement
What this is about
Investors alleged ChemoCentryx and its former President and CEO made material misrepresentations during the class period regarding the ADVOCATE study, the Phase 3 clinical trial of vasculitis drug avacopan, and FDA communications related to avacopan approval.
The background
ChemoCentryx, Inc. Securities Litigation (Class Representative Indiana Public Retirement System) is a securities class action alleging the company and its former President and CEO Dr. Thomas J. Schall violated federal securities laws through misrepresentations about the ADVOCATE study and communications with the FDA regarding avacopan. The parties agreed to a $69,000,000 cash settlement for all persons who purchased ChemoCentryx common stock from November 26, 2019 through May 6, 2021 and were damaged. Claim Forms must be submitted online or postmarked by October 1, 2026; the fairness hearing originally set for October 22, 2026 has been rescheduled to October 29, 2026 at 2:00 p.m. Pacific (Zoom) before Judge Tigar in the N.D. California.
Worth knowing
ChemoCentryx, Inc. Securities Litigation (Class Representative Indiana Public Retirement System) is a securities class action alleging the company and its former President and CEO Dr. Thomas J. Schall violated federal securities laws through misrepresentations about the ADVOCATE study and communications with the FDA regarding avacopan. The parties agreed to a $69,000,000 cash settlement for all persons who purchased ChemoCentryx common stock from November 26, 2019 through May 6, 2021 and were damaged. Claim Forms must be submitted online or postmarked by October 1, 2026; the fairness hearing originally set for October 22, 2026 has been rescheduled to October 29, 2026 at 2:00 p.m. Pacific (Zoom) before Judge Tigar in the N.D. California.
File your claim on the official site →Common questions
How much can I get from the In re ChemoCentryx, Inc. Securities Litigation Settlement?
Pro rata share of $69,000,000 settlement fund based on Recognized Loss under the Plan of Allocation.
What happened in the In re ChemoCentryx, Inc. Securities Litigation Settlement case?
Investors alleged ChemoCentryx and its former President and CEO made material misrepresentations during the class period regarding the ADVOCATE study, the Phase 3 clinical trial of vasculitis drug avacopan, and FDA communications related to avacopan approval.
How do I actually file a claim?
Use the official claim link on this page — it goes directly to the real claims administrator or court-approved site. We never collect claim submissions ourselves and never charge a fee to help you file.
Where does this information come from?
This entry was last verified on September 04, 2026 against its primary source (the official claims administrator, court record, or government page) — linked below. We re-check it, not just copy it once.
Want to know when settlements like this open up?
We check for new Financial Services & Banking claims daily. Tell us your email and we'll send a weekly rundown of what's new — no spam, unsubscribe anytime.